[{"address1": "121 Richmond Street West", "address2": "Penthouse Suite, 1300", "city": "Toronto", "state": "ON", "zip": "M5H2K1", "country": "Canada", "phone": "416 346 7764", "website": "https://www.psyencebiomed.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.", "fullTimeEmployees": 12, "companyOfficers": [{"maxAge": 1, "name": "Mr. Jody  Aufrichtig", "age": 51, "title": "Co-Founder, Executive Chairman & CEO", "yearBorn": 1974, "fiscalYear": 2025, "totalPay": 216667, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Warwick Ron Corden-Lloyd", "age": 45, "title": "CFO & Director", "yearBorn": 1980, "fiscalYear": 2025, "totalPay": 195000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Neil  Maresky M.D.", "age": 61, "title": "Global Head of Clinical Development", "yearBorn": 1964, "fiscalYear": 2025, "totalPay": 390000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Taryn  Vos", "title": "General Counsel", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1767139200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.7682, "open": 0.785, "dayLow": 0.7806, "dayHigh": 0.82, "regularMarketPreviousClose": 0.7682, "regularMarketOpen": 0.785, "regularMarketDayLow": 0.7806, "regularMarketDayHigh": 0.82, "payoutRatio": 0.0, "beta": 0.318, "volume": 298806, "regularMarketVolume": 298806, "averageVolume": 1368585, "averageVolume10days": 331780, "averageDailyVolume10Day": 331780, "bid": 1.08, "ask": 1.89, "bidSize": 2, "askSize": 2, "marketCap": 5110883, "fiftyTwoWeekLow": 0.662, "fiftyTwoWeekHigh": 18.0, "allTimeHigh": 8730.0, "allTimeLow": 0.662, "fiftyDayAverage": 1.76176, "twoHundredDayAverage": 3.665865, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -5652344, "profitMargins": 0.0, "floatShares": 1550489, "sharesOutstanding": 6388604, "sharesShort": 312062, "sharesShortPriorMonth": 99249, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.1667, "heldPercentInsiders": 0.04913, "heldPercentInstitutions": 0.029409999, "shortRatio": 0.15, "shortPercentOfFloat": 0.1667, "impliedSharesOutstanding": 6388604, "bookValue": 6.339, "priceToBook": 0.12620287, "lastFiscalYearEnd": 1743379200, "nextFiscalYearEnd": 1774915200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -3941597, "trailingEps": -62.4, "lastSplitFactor": "125:1000", "lastSplitDate": 1746403200, "enterpriseToEbitda": 1.364, "52WeekChange": -0.9502488, "SandP52WeekChange": 0.19362879, "quoteType": "EQUITY", "currentPrice": 0.8, "recommendationKey": "none", "totalCash": 7149985, "totalCashPerShare": 3.819, "ebitda": -4145455, "totalDebt": 0, "quickRatio": 7.766, "currentRatio": 8.09, "returnOnAssets": -0.34442002, "returnOnEquity": -0.74286, "freeCashflow": -4006023, "operatingCashflow": -4247508, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "PBM", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "postMarketChangePercent": -0.4374981, "postMarketPrice": 0.7965, "postMarketChange": -0.0034999847, "regularMarketChange": 0.0318, "regularMarketDayRange": "0.7806 - 0.82", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1368585, "fiftyTwoWeekLowChange": 0.13800001, "fiftyTwoWeekLowChangePercent": 0.20845923, "fiftyTwoWeekRange": "0.662 - 18.0", "fiftyTwoWeekHighChange": -17.2, "fiftyTwoWeekHighChangePercent": -0.9555556, "fiftyTwoWeekChangePercent": -95.02488, "marketState": "CLOSED", "regularMarketChangePercent": 4.13955, "regularMarketPrice": 0.8, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1639146600000, "corporateActions": [], "postMarketTime": 1768004317, "regularMarketTime": 1767992400, "exchange": "NCM", "messageBoardId": "finmb_698500412", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "shortName": "Psyence Biomedical Ltd.", "longName": "Psyence Biomedical Ltd.", "epsTrailingTwelveMonths": -62.4, "fiftyDayAverageChange": -0.96176, "fiftyDayAverageChangePercent": -0.54590863, "twoHundredDayAverageChange": -2.865865, "twoHundredDayAverageChangePercent": -0.78177047, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-01-26", "prevName": "Psyence Therapeutics Corp.", "nameChangeDate": "2026-01-09", "cryptoTradeable": false, "displayName": "Psyence Biomedical", "trailingPegRatio": null, "__fetch_time": "2026-01-10"}]